Virpath- Influenza, from emergence to control

Afficher tout

Publications

2016

Native and functional isolation of influenza A matrix 2 proton sélective ion channel. Desuzinge E, Mandon E, Traversier A, Champagne A, Bernier L, Balme S, Dejean E, Rosa-Calatrava M and A Jawhari. Protein Expression and Purification. 2016 In press

Critical phases of viral production processes monitored by capacitance. Petiot E, Ansorge S, Rosa-Calatrava M and Kamen A. Journal of Biotechnology. 2016. In press
Impact on antiviral resistance of E119V, I222L and R292K substitutions in influenza A viruses bearing a group-2 neuraminidase (N2, N3, N6, N7, N9).
Gaymard A, Charles-Dufant A, Sabatier M, Cortay JC, Frobert E, Picard C, Casalegno JS, Rosa-Calatrava M, Ferraris O, Valette M, Ottmann M, Lina B and Escuret V.
Journal of Antimicrobial Chemotherapy. 2016 Jul 17

Nucleolin interacts with influenza A nucleoprotein and contributes to viral ribonucleoprotein complexes nuclear trafficking and efficient influenza viral replication.
Terrier O, Carron C, De Chassey B, Dubois J, Traversier A, Julien T, Cartet G, Proust A, Hacot S, Ressnikof D, Lotteau V, Lina B, Diaz JJ, Moules V and Rosa-Calatrava M.
Scientific Report. 2016 Jul 15

Functional balance between Neuraminidase and Hemagglutinin in influenza viruses.
Gaymard A., Le Briand N., Frobert E., Lina B., Escuret V.
Clinical Microbiology and Infection, 2016. doi: 10.1016/j.cmi.2016.07.007.

2015

Clinical Characteristics Are  Similar across Type A and B Influenza Virus Infections. Mosnier A, Caini S, Daviaud I, Nauleau E, Bui TT, Debost E, Bedouret B, Agius  G, van der Werf S, Lina B, Cohen JM; GROG network.
PLoS One. 2015 Sep
1;10(9):e0136186. doi: 10.1371/journal.pone.0136186. PubMed PMID: 26325069;
PubMed Central PMCID: PMC4556513.
https://www-ncbi-nlm-nih-gov.gate1.inist.fr/pubmed/26325069

Platelet activation and aggregation promote lung inflammation and influenza virus pathogenesis. Lê VB, Schneider JG, Boergeling Y, Berri F, Ducatez M, Guerin JL, Adrian I, Errazuriz-Cerda E, Frasquilho S, Antunes L, Lina B, Bordet JC, Jandrot-Perrus M,  Ludwig S, Riteau B.
Am J Respir Crit Care Med. 2015 Apr
1;191(7):804-19. doi: 10.1164/rccm.201406-1031OC. PubMed PMID: 25664391.
https://www-ncbi-nlm-nih-gov.gate1.inist.fr/pubmed/25664391

Ten influenza seasons in France: distribution and timing of influenza A and B circulation, 2003-2013. Mosnier A, Caini S, Daviaud I, Bensoussan JL, Stoll-Keller F, Bui TT, Lina B,  Van der Werf S, Cohen JM; GROG network.
BMC Infect Dis. 2015 Aug 21;15:357. doi: 10.1186/s12879-015-1056-z. PubMed PMID: 26289794;
PubMed Central PMCID: PMC4545988.
https://www-ncbi-nlm-nih-gov.gate1.inist.fr/pubmed/26289794

2014

Influenza viruses and mRNA splicing: doing more with less.
Dubois J, Terrier O, Rosa-Calatrava M.
MBio. 2014 May 13;5(3):e00070-14. doi: 10.1128/mBio.00070-14.

Ultrastructural fingerprints of avian influenza A (H7N9) virus in infected human lung cells.
Terrier O, Carron C, Cartet G, Traversier A, Julien T, Valette M, Lina B, Moules V, Rosa-Calatrava M.
Virology. 2014 May;456-457:39-42. doi: 10.1016/j.virol.2014.03.013. Epub 2014 Mar 28.

Functional balance between the hemagglutinin and neuraminidase of influenza A(H1N1)pdm09 HA D222 variants.
Casalegno JS, Ferraris O, Escuret V, Bouscambert M, Bergeron C, Linès L, Excoffier T, Valette M, Frobert E, Pillet S, Pozzetto B, Lina B, Ottmann M.
PLoS One. 2014 Aug 13;9(8):e104009. doi: 10.1371/journal.pone.0104009. eCollection 2014.

A novel I221L substitution in neuraminidase confers high-level resistance to oseltamivir in influenza B viruses.
Escuret V, Collins PJ, Casalegno JS, Vachieri SG, Cattle N, Ferraris O, Sabatier M, Frobert E, Caro V, Skehel JJ, Gamblin S, Valla F, Valette M, Ottmann M, McCauley JW, Daniels RS, Lina B.
J Infect Dis. 2014 Oct 15;210(8):1260-9. doi: 10.1093/infdis/jiu244. Epub 2014 May 3.

2013

A functional sequence-specific interaction between influenza A virus genomic RNA segments.
Gavazzi C, Yver M, Isel C, Smyth RP, Rosa-Calatrava M, Lina B, Moulès V, Marquet R.
Proc Natl Acad Sci U S A. 2013 Oct 8;110(41):16604-9. doi: 10.1073/pnas.1314419110. Epub 2013 Sep 25.

Influenza NS1 interacts with p53 and alters its binding to p53-responsive genes, in a promoter-dependent manner.
Terrier O, Diederichs A, Dubois J, Cartet G, Lina B, Bourdon JC, Rosa-Calatrava M.
FEBS Lett. 2013 Sep 17;587(18):2965-71. doi: 10.1016/j.febslet.2013.08.006. Epub 2013 Aug 13.

Critical role of segment-specific packaging signals in genetic reassortment of influenza A viruses.
Essere B, Yver M, Gavazzi C, Terrier O, Isel C, Fournier E, Giroux F, Textoris J, Julien T, Socratous C, Rosa-Calatrava M, Lina B, Marquet R, Moules V.
Proc Natl Acad Sci U S A. 2013 Oct 1;110(40):E3840-8. doi: 10.1073/pnas.1308649110. Epub 2013 Sep 16.

p53 protein isoforms: key regulators in the front line of pathogen infections?
Terrier O, Bourdon JC, Rosa-Calatrava M.
PLoS Pathog. 2013;9(4):e1003246. doi: 10.1371/journal.ppat.1003246. Epub 2013 Apr 4.

Host microRNA molecular signatures associated with human H1N1 and H3N2 influenza A viruses reveal an unanticipated antiviral activity for miR-146a.
Terrier O, Textoris J, Carron C, Marcel V, Bourdon JC, Rosa-Calatrava M.
J Gen Virol. 2013 May;94(Pt 5):985-95. doi: 10.1099/vir.0.049528-0. Epub 2013 Jan 23.

Interaction network linking the human H3N2 influenza A virus genomic RNA segments.
Fournier E, Moules V, Essere B, Paillart JC, Sirbat JD, Cavalier A, Rolland JP, Thomas D, Lina B, Isel C, Marquet R.
Vaccine. 2012 Dec 7;30(51):7359-67. doi: 10.1016/j.vaccine.2012.09.079. Epub 2012 Oct 9.

An in vitro network of intermolecular interactions between viral RNA segments of an avian H5N2 influenza A virus: comparison with a human H3N2 virus.
Gavazzi C, Isel C, Fournier E, Moules V, Cavalier A, Thomas D, Lina B, Marquet R.
Nucleic Acids Res. 2013 Jan;41(2):1241-54. doi: 10.1093/nar/gks1181. Epub 2012 Dec 5.

Recent developments with live-attenuated recombinant paramyxovirus vaccines.
Le Bayon JC, Lina B, Rosa-Calatrava M, Boivin G.
Rev Med Virol. 2013 Jan;23(1):15-34. doi: 10.1002/rmv.1717. Epub 2012 May 8.

2012

The influenza fingerprints: NS1 and M1 proteins contribute to specific host cell ultrastructure signatures upon infection by different influenza A viruses.
Terrier O, Moules V, Carron C, Cartet G, Frobert E, Yver M, Traversier A, Wolff T, Riteau B, Naffakh N, Lina B, Diaz JJ, Rosa-Calatrava M.
Virology. 2012 Oct 10;432(1):204-18. doi: 10.1016/j.virol.2012.05.019. Epub 2012 Jul 6.

H1N1 influenza A virus neuraminidase modulates infectivity in mice.
Ferraris O, Escuret V, Bouscambert M, Casalegno JS, Jacquot F, Raoul H, Caro V, Valette M, Lina B, Ottmann M.
Antiviral Res. 2012 Mar;93(3):374-80. doi: 10.1016/j.antiviral.2012.01.008. Epub 2012 Feb 1.

Influenza A viruses control expression of proviral human p53 isoforms p53β and Delta133p53α.
Terrier O, Marcel V, Cartet G, Lane DP, Lina B, Rosa-Calatrava M, Bourdon JC.
J Virol. 2012 Aug;86(16):8452-60. doi: 10.1128/JVI.07143-11. Epub 2012 May 30.

2011
Importance of viral genomic composition in modulating glycoprotein content on the surface of influenza virus particles.
Moulès V, Terrier O, Yver M, Riteau B, Moriscot C, Ferraris O, Julien T, Giudice E, Rolland JP, Erny A, Bouscambert-Duchamp M, Frobert E, Rosa-Calatrava M, Pu Lin Y, Hay A, Thomas D, Schoehn G, Lina B.
Virology. 2011 May 25;414(1):51-62. doi: 10.1016/j.virol.2011.03.011. Epub 2011 Apr 5.

Combinatorial effect of two framework mutations (E119V and I222L) in the neuraminidase active site of H3N2 influenza virus on resistance to oseltamivir.
Richard M, Ferraris O, Erny A, Barthélémy M, Traversier A, Sabatier M, Hay A, Lin YP, Russell RJ, Lina B.
Antimicrob Agents Chemother. 2011 Jun;55(6):2942-52. doi: 10.1128/AAC.01699-10. Epub 2011 Mar 21.

2010

Gene expression signature-based screening identifies new broadly effective influenza a antivirals.
Josset L, Textoris J, Loriod B, Ferraris O, Moules V, Lina B, N’guyen C, Diaz JJ, Rosa-Calatrava M.
PLoS One. 2010 Oct 4;5(10). pii: e13169. doi: 10.1371/journal.pone.0013169.

Novel influenza A(H1N1) 2009 in vitro reassortant viruses with oseltamivir resistance.
Ottmann M, Duchamp MB, Casalegno JS, Frobert E, Moulès V, Ferraris O, Valette M, Escuret V, Lina B.
Antivir Ther. 2010;15(5):721-6. doi: 10.3851/IMP1576.

Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial.
Duval X, van der Werf S, Blanchon T, Mosnier A, Bouscambert-Duchamp M, Tibi A, Enouf V, Charlois-Ou C, Vincent C, Andreoletti L, Tubach F, Lina B, Mentré F, Leport C; Bivir Study Group.
PLoS Med. 2010 Nov 2;7(11):e1000362. doi: 10.1371/journal.pmed.1000362.

In vitro characterization of naturally occurring influenza H3NA- viruses lacking the NA gene segment: toward a new mechanism of viral resistance?
Moules V, Ferraris O, Terrier O, Giudice E, Yver M, Rolland JP, Bouscambert-Duchamp M, Bergeron C, Ottmann M, Fournier E, Traversier A, Boule C, Rivoire A, Lin Y, Hay A, Valette M, Marquet R, Rosa-Calatrava M, Naffakh N, Schoehn G, Thomas D, Lina B.
Virology. 2010 Sep 1;404(2):215-24. doi: 10.1016/j.virol.2010.04.030.

Patents

Nouvelles compositions antivirales pour le traitement des infections liées aux coronavirus
Terrier O, Anais Proust, Moules V et Rosa-Calatrava M.
INSERM, CNRS, Université Claude Bernard Lyon 1.
FR 16 60223 (2016-10-21)

New antiviral composition for influenza treatment.
Terrier O, Textoris J, Pizzorno A, Padey B, Boivin G et Rosa-Calatrava M.
INSERM, Université Claude Bernard Lyon 1, Université Laval, Hospices Civils de Lyon.
FR 16 53057 (2016-04-07)

New antiviral compounds for influenza treatment.
Nouvelles compositions antivirales pour le traitement de la grippe
Terrier O, Textoris J, Pizzorno A, Boivin G et Rosa-Calatrava M.
INSERM, Université Claude Bernard Lyon 1, Université Laval, Hospices Civils de Lyon.
FR 15 52284 (2015-03-18) – PCT/ep2016/056036

Vaccine antigen manufacturing process, vaccine antigen achieved and application
Procédé de préparation d’un antigène vaccinal, antigène vaccinal obtenu et utilisations
Traversier A, Dejean E, Mandon E et Rosa-Calatrava M.
INSERM, Université Claude Bernard Lyon 1, Calixar, Hospices Civils de Lyon
FR 1458124 (2014-08-29)

Sulphated arabinogalactans, apiogalacturonans and sulphated heteroglycan for treating diseases caused by the influenza virus.
Lina B, Ferraris O, Vo Ho H, Cosset FL, Szecsi J, Heyraud A, Lortat)Jacob H, Bartoli J, Sadir R, Livache T, Darblade B, Havet S, Bonnet S.
INSERM, CNRS, CEA, Elicityl
FR20110050049, 20110104 WO2012FR50017 20120103

Method for improving the production of influenza viruses and vaccine seeds.
Procédés pour améliorer la production de virus et semences vaccinales influenza
Terrier O, Bourdon JC,  Rosa-Calatrava M.
CNRS, Université de Lyon, HCL, Université de Dundee.
FR 10/59132 – WO 2012059696 (2010-11-05)

Modified viral strains, and method for improving the production of vaccine seeds of the influenza virus
Modification du fond génétique PR8 pour l’optimisation qualitative et quantitative de la production des antigènes vaccinaux HA et NA des virus influenza (PB1).
V. Moules, M. Yver, O. Ferraris, M.Rosa-Calatrava.
CNRS, Université de Lyon, HCL.
FR 10/55716 – WO 2012007380 (2010-07-13)

Cells modified for virus production by inhibition of the hipk2 gene.
Procédés pour optimiser la production virale par l’inactivation ou l’inhibition du gène HIPK2 et cellules modifiées pour la production virale
B. Lina, JJ. Diaz, M. Rosa-Calatrava.
CNRS, Université de Lyon, HCL.
FR 10/51041 – PCT/EP2011/052194 – WO 2011098615 (2010-02-15)

Pharmaceutical or veterinary antiviral compositions
Composition antivirale pharmaceutique ou vétérinaire
L. Josset, J. Textoris, JJ. Diaz, M. Rosa-Calatrava.
CNRS, INSERM, UCBL, HCL.
FR 0958810 – PCT/EP2010/069023- WO 2011069990 (2011-06-16)

Mutant proteins of the f protein of piv-5 and piv-2
Protéines mutantes de la protéine F de PIV-5 et de PIV-2
O. Terrier, F. Durupt, M. Rosa-Calatrava.
CNRS, Université de Lyon, HCL.
FR 08/06547 – PCT/FR2009/001317 – WO 2010/058100 (2010-05-27)

Hpiv-2 variants and medical applications thereof
Variants de Hpiv-2, et leurs applications médicales
B. Lina, O. Terrier, D. Thouvenot.
CNRS, HCL.
FR2918995 (A1) – WO2008FR01067 20080718 – EP20080831374 – EP2170935 (A2) (2010-04-07)

NOS TUTELLES ET PARTENAIRES